US EditionSatio completes development intradermal drug delivery system
- Satio announced the completion of its SBIR contract for its drug delivery system.
- ARPA-H awarded Satio a $3.5 million contract in September 2023 to develop SatioRx.
- The SatioRx device delivers liquid medicine via a microneedle array, intradermally or subcutaneously.
- Namal Nawana said ARPA-H support enabled two innovations: remote control and automated intradermal delivery.
- Satio's work advances decentralized care and addresses chronic disease, though products are not FDA approved.
23 Articles
23 Articles
Rutland Herald
Satio Successfully Completes Development and Testing of Novel At-Home, Remotely Controllable, Intradermal Drug Delivery System, Achieving the First Fully Executed ARPA-H Small Business Contract
BOSTON, April 7, 2025 /PRNewswire/ -- Satio, Inc. is pleased to announce the successful completion of a Small Business Innovation Research contract awarded by the Advanced Research Projects Agency for Health (ARPA-H).
Satio completes development intradermal drug delivery system
The SatioRx drug delivery device. [Screenshot taken from Satio demonstration video]Satio announced today that it completed a Small Business Innovation Research (SBIR) contract for its intradermal drug delivery system. The NIH’s Advanced Research Projects Agency for Health (ARPA-H) awarded Satio the $3.5 million in September 2023. This contract aimed to help the company develop SatioRx, its intradermal drug delivery device. The compact, inexpensi…
Coverage Details
Bias Distribution
- 55% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
